Rubinstein-Taybi syndrome and keloids

Completed

• Conditions: itching scar; keloid; 10083624; 10014982

• Registration Number: NL-OMON38183
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

Patients with the Rubinstein Taybi syndrome
Patients with keloids
Age 18 years or above
Written informed consent
For the biopsy study: the patient needs general anaesthesia for a planned intervention for patient care reasons

Exclusion Criteria

Insufficient understanding of the purpose of the study by parents / other legal representative
Age < 18 years

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The clinical characteristics of keloids<br /><br>The histological characteristics of keloids<br /><br>The moleculair and cell-biological characteristics of keloids in RTS, mainly<br /><br>the TGF beta pathway and HAT function</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>